Jaguar Animal Health (JAGX) AI Stock Analysis

• Market Cap: $4.41M
• Dividend Yield: N/A
• Average Volume (3M): 130.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: 15.95%
• EPS Growth: 92.33%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -10.26
• Shares Outstanding: 2,174,841
• 10 Day Avg. Volume: 190,678
• 30 Day Avg. Volume: 130,588
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 7.31
• Enterprise Value/Revenue: 2.74
• Enterprise Value/Gross Profit: 3.34
• Enterprise Value/Ebitda: -0.82
• 1Y Price Target: $1.50
• Price Target Upside: -23.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: $2.00 ▲(2.04% Upside)

Jaguar Animal Health's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and consistent losses. Technical indicators suggest a bearish trend, and valuation metrics are poor. While the earnings call provided some positive insights, they are overshadowed by ongoing financial challenges.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, enhancing long-term financial stability.

Regulatory Advancements

Regulatory advancements for crofelemer can expand market access and drive future revenue growth, strengthening the company's competitive position.

Clinical Trial Success

Successful clinical trials enhance product credibility and open new therapeutic markets, supporting long-term growth and innovation.

Negative Factors

High Leverage

High leverage increases financial risk and limits strategic flexibility, potentially impacting future growth and investment capacity.

Negative Cash Flow

Negative cash flow trends indicate challenges in sustaining operations and funding growth, necessitating improved cash management strategies.

Operational Losses

Rising operational losses highlight inefficiencies and cost management issues, which can hinder profitability and long-term sustainability.

Jaguar Animal Health Business Overview & Revenue Model

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

How the Company Makes Money

Jaguar Animal Health generates revenue primarily through the sale of its pharmaceutical products and veterinary therapeutics. The company has established a revenue model that includes direct sales to veterinarians and animal health distributors, as well as partnerships with larger pharmaceutical companies for product development and distribution. Key revenue streams include prescription medications and potential royalties from collaborations. Additionally, Jaguar may engage in licensing agreements for its proprietary technologies, further enhancing its financial performance. Significant partnerships with veterinary practices and discussions with animal food companies also contribute to its earnings, as they help broaden the reach and application of its products in the market.

Jaguar Animal Health Financial Statement Overview

Summary

Jaguar Animal Health faces substantial financial challenges characterized by high leverage, consistent net losses, and negative cash flows. Despite some revenue growth and strong gross margins, the company struggles with operational efficiencies and debt management.

Income Statement

Jaguar Animal Health has shown a mixed performance with inconsistent revenue growth. The revenue grew by approximately 18.38% from 2023 to 2024 but showed a decline previously. Gross profit margins are reasonably high, but the company struggles with negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a Debt-to-Equity ratio of approximately 5.63 in 2024, reflecting significant reliance on debt financing. The return on equity is negative due to consistent net losses, and the equity ratio is low, suggesting financial instability and potential risks related to excessive debt.

Cash Flow

Cash flow analysis reveals a negative trend in free and operating cash flows, although there was a slight improvement from 2023 to 2024. The company managed to secure significant financing cash flows, which have been covering operational deficits. However, the negative free cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.77M	11.69M	9.76M	11.96M	4.33M	9.38M
Gross Profit	9.67M	9.73M	7.72M	9.94M	2.00M	6.11M
EBITDA	-39.29M	-36.66M	-33.13M	-33.38M	-42.35M	-28.74M
Net Income	-40.65M	-38.49M	-41.30M	-47.45M	-60.25M	-36.79M
Balance Sheet
Total Assets	48.27M	53.42M	50.76M	47.45M	53.27M	42.84M
Cash, Cash Equivalents and Short-Term Investments	2.21M	8.00M	6.47M	5.47M	17.05M	8.09M
Total Debt	30.53M	36.53M	37.09M	34.84M	29.36M	16.21M
Total Liabilities	41.39M	46.93M	45.87M	48.81M	41.41M	25.64M
Stockholders Equity	7.99M	9.77M	4.96M	-657.00K	11.61M	17.20M
Cash Flow
Free Cash Flow	-27.88M	-29.61M	-33.24M	-34.78M	-34.98M	-15.29M
Operating Cash Flow	-27.68M	-29.38M	-33.24M	-33.10M	-34.97M	-15.28M
Investing Cash Flow	-215.00K	-231.00K	1.23M	-1.68M	-6.00K	-7.00K
Financing Cash Flow	13.98M	31.20M	34.23M	23.18M	43.94M	19.49M

Jaguar Animal Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Neutral. The current price of 1.96 is above the 20-day moving average (MA) of 1.84, below the 50-day MA of 2.14, and below the 200-day MA of 10.91, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 48.99 is Neutral, neither overbought nor oversold. The STOCH value of 75.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JAGX.

Jaguar Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
JAGX	42 Neutral	$4.41M	―	-296.91%	―	15.95%	92.33%
SXTP	41 Neutral	$5.83M	―	-285.78%	―	120.67%	-456.33%
SNGX	39 Underperform	$11.91M	―	-402.19%	―	―	59.81%
GLMD	28 Underperform	$8.49M	―	-53.99%	―	―	56.31%
REVB	28 Underperform	$3.40M	―	-340.81%	―	―	94.99%
DRMA	15 Underperform	$3.68M	―	-231.27%	―	―	85.78%

Jaguar Animal Health Corporate Events

Jaguar Health Announces Promising Trial Results

On August 19, 2025, Jaguar Health held its Annual Meeting of Stockholders, where seven proposals were approved, including the election of directors and amendments to stock plans. The company also announced promising results from trials of crofelemer for gastrointestinal conditions and outlined plans for regulatory pathways and business development partnerships, potentially impacting its market strategy and stakeholder interests.

Jaguar Health Extends Market Offering Agreement

On August 14, 2025, Jaguar Health, Inc. announced an amendment to its At the Market Offering Agreement, extending Lucid Capital Markets, LLC’s role as a Manager until December 31, 2025. This amendment, filed with the SEC, ensures that Lucid will continue its managerial role alongside Ladenburg Thalmann & Co. Inc. until the end of 2025, after which Ladenburg will become the sole Manager unless further extended.

Jaguar Animal Health Issues Series M Preferred Stock

On June 27, 2025, Jaguar Health, Inc. entered into exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, issuing Series M Preferred Stock in exchange for reductions in outstanding royalty interests. This strategic move allows Jaguar Health to manage its financial obligations while offering stakeholders a structured investment opportunity through the Series M Preferred Stock, which includes specific rights and limitations, impacting the company’s capital structure and market positioning.

Jaguar Animal Health Extends Maturity Date for Notes

On June 24, 2025, Jaguar Health, Inc. announced an extension of the maturity date for $2.57 million of convertible promissory notes from its March 2025 bridge financing, now maturing on January 30, 2026. This extension, involving participation from the company’s CEO, board members, and other investors, aims to support Jaguar’s strategic goals, including partnerships for non-dilutive funding and advancing development programs for crofelemer in treating various conditions.